Review of Allogeneic Dentin Graft for Maxillofacial Bone Defects
Jeong-Kui Ku1, Yeong Kon Jeong2, In-Woong Um3
1Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry, Seoul, Republic of Korea.
Tissue Engineering. Part C, Methods
|August 10, 2021
Summary
Allogeneic demineralized dentin matrix (allo-DDM) shows osteoinductivity for maxillofacial bone defects. This review confirms allo-DDM
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Oral and Maxillofacial Surgery
Background:
- Autogenous demineralized dentin matrix (auto-DDM) is effective but has limitations.
- Allogeneic demineralized dentin matrix (allo-DDM) presents a potential alternative.
- Limited research exists on allo-DDM's osteoinductivity and antigenicity.
Purpose of the Study:
- To review all human studies on allogeneic dentin grafts for maxillofacial bone defects.
- To evaluate the osteoinductivity and antigenicity of allo-DDM in clinical settings.
Main Methods:
- Systematic review of human clinical studies.
- Analysis of studies investigating allogeneic dentin graft applications.
- Assessment of reported osteoinductivity and antigenicity outcomes.
Main Results:
- Clinical studies demonstrate the osteoinductivity of allo-DDM.
- Allo-DDM facilitates bone regeneration in both skeletal and extraskeletal sites.
- Occasional antigenicity was noted but did not preclude its clinical utility.
Conclusions:
- Allogeneic demineralized dentin matrix is a viable option for maxillofacial bone defect management.
- Allo-DDM exhibits significant osteoinductive properties in human clinical applications.
- Further research may be needed to fully understand and mitigate potential antigenicity.
More Related Videos
08:41Calvarial Model of Bone Augmentation in Rabbit for Assessment of Bone Growth and Neovascularization in Bone Substitution Materials
Published on: August 13, 2019
8.5K
06:05Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration
Published on: July 14, 2023
1.2K
